Consistent with this causative link are our findings that the majority of the late non-CH mutations identified in our cohort were missense mutation (75.2%, Figure 1D) and that the patients with AITL/PTCL-NOS have a 172.3-fold increased risk for development of lung cancer compared to the age-matched/adjusted general population (Figure 2D). Here, C4B is linked to lung cancer.